Chemoradiotherapy versus radiotherapy in high risk salivary gland cancer.
Chemoradiotherapy
Lymph node metastasis burden
Radiotherapy
Salivary gland cancer
Survival
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
received:
21
04
2024
accepted:
16
06
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
11
7
2024
Statut:
epublish
Résumé
The aim of this study was to investigate the potential survival benefits associated with chemoradiotherapy (CRT) as opposed to radiotherapy (RT) in patients with resected high-risk salivary gland cancer (SGC), with a specific focus on determining whether these benefits are influenced by the number of high-risk variables. Patients who underwent surgical treatment for high-risk SGC were retrospectively enrolled and categorized into either CRT or RT groups. The impact of adjuvant therapy on locoregional control (LRC) and overall survival (OS) was assessed using a multivariable Cox model. A total of 152 patients were included following propensity score-matching. In comparison to RT, CRT did not demonstrate a significant survival advantage in terms of LRC (p = 0.485, HR: 1.14, 95%CI: 0.36-4.22) and OS (p = 0.367, HR: 0.99, 95%CI: 0.17-3.87) in entire population. But among patients with T3/4 stage, high-grade tumors, and 5 or more positive lymph nodes, the addition of chemotherapy to RT significantly (p = 0.042) correlated with a 15% reduction in the risk of cancer recurrence (95%CI: 4-54%). Conversely, in other subgroups with varying combinations of high-risk variables, CRT did not provide additional survival benefits for LRC and OS compared to RT. Adjuvant chemotherapy may be considered in conjunction with RT specifically in cases where there is a presence of T3/4 stage, high-grade tumors, and 5 or more metastatic lymph nodes in high-risk SGC.
Identifiants
pubmed: 38992685
doi: 10.1186/s12957-024-03456-9
pii: 10.1186/s12957-024-03456-9
doi:
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
181Informations de copyright
© 2024. The Author(s).
Références
Ho AS, Luu M, Balzer BL, Aro K, Jang JK, Mita AC, Scher KS, Mallen-St Clair J, Vasquez M, Bastien AJ, Epstein JB, Lin DC, Chen MM, Zumsteg ZS. Comparative impact of grade on mortality across salivary cancers: a novel, unifying staging system. Head Neck. 2023;45:2028–39.
doi: 10.1002/hed.27429
pubmed: 37345665
Skálová A, Hyrcza MD, Leivo I. Update from the 5th Edition of the World Health Organization Classification of Head and Neck tumors: salivary glands. Head Neck Pathol. 2022;16:40–53.
doi: 10.1007/s12105-022-01420-1
pubmed: 35312980
pmcid: 9018948
Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D, Birkeland AC, Brizel DM, Busse PM, Cmelak AJ, Colevas AD, Eisele DW, Galloway T, Geiger JL, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Mell LK, Mittal BB, Pinto HA, Rocco JW, Rodriguez CP, Savvides PS, Schwartz D, Shah JP, Sher D, St John M, Weber RS, Weinstein G, Worden F, Yang Bruce J, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines® insights: Head and Neck cancers, Version 1.2022. J Natl Compr Canc Netw. 2022;20:224–34.
doi: 10.6004/jnccn.2022.0016
pubmed: 35276673
Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: analysis of 8580 patients in the National Cancer Database. Head Neck. 2018;40:1343–55.
doi: 10.1002/hed.24984
pubmed: 29756412
Aro K, Ho AS, Luu M, Kim S, Tighiouart M, Yoshida EJ, Mallen-St Clair J, Shiao SL, Leivo I, Zumsteg ZS. Survival impact of adjuvant therapy in Salivary Gland Cancers following Resection and Neck Dissection. Otolaryngol Head Neck Surg. 2019;160:1048–57.
doi: 10.1177/0194599819827851
pubmed: 30721113
Giridhar P, Gupta P, Mallick S, Upadhyay AD, Rath GK. Impact of adjuvant therapy on survival in patients with myoepithelial carcinoma: a systematic review and individual patient data analysis of 691 patients. Radiother Oncol. 2019;140:125–30.
doi: 10.1016/j.radonc.2019.06.017
pubmed: 31276988
Gordon AJ, Chow MS, Patel A, Hu KS, Li Z, Jacobson AS, Vaezi AE, Tam MM, Givi B. Adoption of adjuvant chemotherapy in high-risk salivary gland malignancies. Head Neck. 2023;45:167–77.
doi: 10.1002/hed.27222
pubmed: 36245302
Patel AM, Haleem A, Choudhry HS, Povolotskiy R, Roden DF. Patterns and trends in Adjuvant Therapy for Major Salivary Gland Cancer. Otolaryngol Head Neck Surg. 2024. https://doi.org/10.1002/ohn.715 .
doi: 10.1002/ohn.715
pubmed: 38967295
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.
doi: 10.1056/NEJMoa032641
pubmed: 15128894
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK. Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.
doi: 10.1056/NEJMoa032646
pubmed: 15128893
Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefèbvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843–50.
doi: 10.1002/hed.20279
pubmed: 16161069
Amini A, Waxweiler TV, Brower JV, Jones BL, McDermott JD, Raben D, Ghosh D, Bowles DW, Karam SD. Association of Adjuvant Chemoradiotherapy vs Radiotherapy alone with survival in patients with resected major salivary gland carcinoma: data from the National Cancer Data Base. JAMA Otolaryngol Head Neck Surg. 2016;142:1100–10.
doi: 10.1001/jamaoto.2016.2168
pubmed: 27541166
Gebhardt BJ, Ohr JP, Ferris RL, Duvvuri U, Kim S, Johnson JT, Heron DE, Clump DA 2. Concurrent chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland malignancies. Am J Clin Oncol. 2018;41:888–93.
doi: 10.1097/COC.0000000000000386
pubmed: 28394767
pmcid: 6587550
Kang NW, Kuo YH, Wu HC, Ho CH, Chen YC, Yang CC. No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer. Sci Rep. 2022;12:20862.
doi: 10.1038/s41598-022-25468-9
pubmed: 36460788
pmcid: 9718855
Cheraghlou S, Schettino A, Zogg CK, Otremba MD, Bhatia A, Park HS, Osborn HA, Mehra S, Yarbrough WG, Judson BL. Adjuvant chemotherapy is Associated with Improved Survival for late-stage salivary squamous cell carcinoma. Laryngoscope. 2019;129:883–9.
doi: 10.1002/lary.27444
pubmed: 30151947
Little R. A test of missing completely at random for multivariable data with missing values. J Am Stat Assoc. 1988;83:1198–202.
doi: 10.1080/01621459.1988.10478722
van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16:219–42.
doi: 10.1177/0962280206074463
pubmed: 17621469
Bhushan K, Sharma ML, Gupta DK. Chemotherapy for salivary gland malignant carcinoma: Meta-analysis and systemic review. Indian J Otolaryngol Head Neck Surg. 2024;76:123–9.
doi: 10.1007/s12070-023-04104-6
pubmed: 38440426